Ligand Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Ligand Pharma (LGND) Tops Q2 EPS by 13c
July 30, 2019 8:04 AM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $0.68, $0.13 better than the analyst estimate of $0.55. Revenue for the quarter came in at $25 million versus the consensus estimate of $21.01 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
... More